Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL
In Partnership With:
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
Sequential treatment is the future of CLL, says Chavez, including the combination of ibrutinib plus venetoxclax and combinations with monoclonal antibodies.
Ibrutinib plus venetoclax is an interesting combination, Chavez says, and further results will be presented at the 2017 ASH Annual Meeting to confirm its potential in this disease.
Related Videos
Related Content
